Caplin Point Laboratories Limited has entered into a license and distribution agreement with the Cambridge (UK) based Cycle Pharmaceuticals Limited. Under this agreement, Caplin Point will be responsible for developing and manufacturing identified liquid injectable products whereas Cycle Pharmaceuticals Limited will be holding this ANDA and commercialise the same in USA.
This is a product specific agreement for the USA. Currently, one product is featuring in the contract.
“Caplin Point has already received milestone payment for one product and the product development cum dossier preparation have just commenced,” said Caplin Point in a BSE filing.